


RealRate

PHARMACEUTICAL 2021



Turning Point Therapeutics Inc. Rank 52 of 409







PHARMACEUTICAL 2021





Turning Point Therapeutics Inc. Rank 52 of 409

The relative strengths and weaknesses of Turning Point Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Turning Point Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 212% points. The greatest weakness of Turning Point Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 101%, being 455% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	1,130,679
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,392
Liabilities, Non-Current	0
Other Assets	3,430
Other Compr. Net Income	-62
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	2,604
Research and Development	113,411
Revenues	29,544
Selling, General and Administrative Expense	73,425

Output Variable	Value in 1000 USD
Assets	1,136,713
Liabilities	24,392
Expenses	186,836
Stockholders Equity	1,112,321
Net Income	-157,292
Comprehensive Net Income	-157,323
Economic Capital Ratio	101%

